Black Diamond Therapeutics, Inc. (BDTX) stock

BDTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 7/30

$1.52−0.09 (-5.59%)

Close on Nov 12, 2026Market cap $87.33MP/E –Yield –

Black Diamond Therapeutics EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

Black Diamond Therapeutics's EV/EBITDA was 1.8× on Apr 30, 2026.

Period	Period end	Value	Change (pts)
2026	Apr 30, 2026	1.8×	+1.6
2025	Dec 31, 2025	0.2×	–

Parsed from the XBRL in Black Diamond Therapeutics's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is BDTX.

Revenue growth-100.0% · median 7.2%

Advertisement
300 × 250

See a number that looks wrong?